Cholesterol emboli syndrome natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cholesterol emboli syndrome}} | {{Cholesterol emboli syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}}{{NN}} | ||
==Overview== | ==Overview== | ||
Common complications of [[Cholesterol emboli syndrome]] include [[atheroembolic]] [[renal disease]], [[acute kidney injury]], [[chronic kidney disease]], [[myocardial infarction]], [[cerebrovascular accident]] [[bowel ischemia]], [[liver failure]], [[end organ damage]] and death. Prognosis is generally poor, and the incidence of mortality among patients with [[Cholesterol emboli syndrome]] is approximately 63-80 %. | |||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
* | *Common complications of [[Cholesterol emboli syndrome]] include [[atheroembolic]] [[renal disease]], [[acute kidney injury]], [[chronic kidney disease]], [[myocardial infarction]], [[cerebrovascular accident]] [[bowel ischemia]], [[liver failure]], [[end organ damage]] and death. <ref name="AgrawalZiccardi2018">{{cite journal|last1=Agrawal|first1=Akanksha|last2=Ziccardi|first2=Mary Rodriguez|last3=Witzke|first3=Christian|last4=Palacios|first4=Igor|last5=Rangaswami|first5=Janani|title=Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions|journal=Journal of Interventional Cardiology|volume=31|issue=3|year=2018|pages=407–415|issn=08964327|doi=10.1111/joic.12483}}</ref><ref name="Ozkok2019">{{cite journal|last1=Ozkok|first1=Abdullah|title=<p>Cholesterol-embolization syndrome: current perspectives</p>|journal=Vascular Health and Risk Management|volume=Volume 15|year=2019|pages=209–220|issn=1178-2048|doi=10.2147/VHRM.S175150}}</ref> | ||
*Prognosis is generally poor, and the incidence of mortality among patients with [[Cholesterol emboli syndrome]] is approximately 63-80 %.<ref name="AgrawalZiccardi2018">{{cite journal|last1=Agrawal|first1=Akanksha|last2=Ziccardi|first2=Mary Rodriguez|last3=Witzke|first3=Christian|last4=Palacios|first4=Igor|last5=Rangaswami|first5=Janani|title=Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions|journal=Journal of Interventional Cardiology|volume=31|issue=3|year=2018|pages=407–415|issn=08964327|doi=10.1111/joic.12483}}</ref><ref name="FineKapoor2016">{{cite journal|last1=Fine|first1=Michael J.|last2=Kapoor|first2=Wishwa|last3=Falanga|first3=Vincent|title=Cholesterol Crystal Embolization: A Review of 221 Cases in the English Literature|journal=Angiology|volume=38|issue=10|year=2016|pages=769–784|issn=0003-3197|doi=10.1177/000331978703801007}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Line 15: | Line 16: | ||
[[Category:Vascular surgery]] | [[Category:Vascular surgery]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:need English review]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 14:06, 10 February 2021
Cholesterol emboli syndrome Microchapters |
Differentiating Cholesterol emboli syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cholesterol emboli syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Cholesterol emboli syndrome natural history, complications and prognosis |
FDA on Cholesterol emboli syndrome natural history, complications and prognosis |
CDC on Cholesterol emboli syndrome natural history, complications and prognosis |
Cholesterol emboli syndrome natural history, complications and prognosis in the news |
Blogs on Cholesterol emboli syndrome natural history, complications and prognosis |
Directions to Hospitals Treating Cholesterol emboli syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]
Overview
Common complications of Cholesterol emboli syndrome include atheroembolic renal disease, acute kidney injury, chronic kidney disease, myocardial infarction, cerebrovascular accident bowel ischemia, liver failure, end organ damage and death. Prognosis is generally poor, and the incidence of mortality among patients with Cholesterol emboli syndrome is approximately 63-80 %.
Natural History, Complications and Prognosis
- Common complications of Cholesterol emboli syndrome include atheroembolic renal disease, acute kidney injury, chronic kidney disease, myocardial infarction, cerebrovascular accident bowel ischemia, liver failure, end organ damage and death. [1][2]
- Prognosis is generally poor, and the incidence of mortality among patients with Cholesterol emboli syndrome is approximately 63-80 %.[1][3]
References
- ↑ 1.0 1.1 Agrawal, Akanksha; Ziccardi, Mary Rodriguez; Witzke, Christian; Palacios, Igor; Rangaswami, Janani (2018). "Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions". Journal of Interventional Cardiology. 31 (3): 407–415. doi:10.1111/joic.12483. ISSN 0896-4327.
- ↑ Ozkok, Abdullah (2019). "
Cholesterol-embolization syndrome: current perspectives
". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048. - ↑ Fine, Michael J.; Kapoor, Wishwa; Falanga, Vincent (2016). "Cholesterol Crystal Embolization: A Review of 221 Cases in the English Literature". Angiology. 38 (10): 769–784. doi:10.1177/000331978703801007. ISSN 0003-3197.